Молекулярно-цитогенетическая диагностика рака мочевого пузыря Medline.ru - медико-биологический информационный портал Медлайн.ру

1. Bubendorf L., Grilli B., Sauter G., Mihatsch M.J., Gasser T.C., Dalquen P. Multiprobe FISH

for enhanced detection of bladder cancer in voided urine specimens and bladder washings. //

Am. J. Clin. Pathol. - 2001. - V.116, N.1. - P.79-86.

2. Maier U., Simak R., Neuhold N. The clinical value of urinary cytology: 12 years of experience

with 615 patients. // J. Clin. Pathol. - 1995. - V.48. - P.314-317.

3. Main C., Pycha A., Wiener H., et al. Immunocyt: a new tool for detecting transitional cell

cancer of the urinary tract. // J Urol. - 1999. - V.161. - P.1486-1489.

4. Ross J.S., Cohen M.B. Ancillary methods for the detection of recurrent urothelial neoplasma.

// Cancer. - 2000. - V.90. - P.75-86.

5. Glas A.S., Roos D., Deutekom M., Zwinderman A.H., Bossuyt P.M.M., Kurth K.H. Tumor

markers in the diagnosis of primary bladder cancer. A systematic review. // The Journal of

Urology. - 2003. - V.169. - P.1975-1982

6. Amiel G.E., Shu T., Lerner S.P. Alternatives to cytology in the management of non-muscle

invasive bladder cancer. // Curr. Treat. Options. Oncol. - 2004. - V.5, N.5. - P.377-389.

7. Аль-Шукри С.Х., Корнеев И.А. Общие принципы лечения больных раком мочевого

пузыря. Значение клинических, гистологических и биологических факторов прогноза для

выбора метода лечения. // Практическая онкология. - 2003. - V.4, N.4. - P.204-213.

8. Mudle S.D., Sokolova I. Clinical implications of advanced molecular cytogenetics in cancer. //

Expert Rev. Mol. Diagn. - 2004. - V.4, N.1. - P. 71-81.

9. Sandberg A.A., Berger C.S. Review of chromosome studies in urological tumors. II.

Cytogenetics and molecular genetics of bladder cancer. // J Urol. - 1994. - V.151. - P.545-560.

Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and

bladder washings. // Am. J. Clin. Pathol. - 2001. - V.116, N.1. - P.79-86.

10. Sidransky D., Messing E. Molecular genetics and biochemical mechanisms in bladder

cancer. Oncogenes, tumor suppressor genes, and growth factors (review). // Urol. Clin. N. Am. -

1992. - V.19. - P.629-639.

11. Knowles M.A. Molecular genetics of bladder cancer (review). // Br J Urol - 1995. - V.75. -

P.57-66.

12. Имянитов Е.Н., Хансон К.П. Эпидемиология и биология рака мочевого пузыря. //

Практическая онкология. - 2003. - Т.4, N.4. - C.191-195.

13. Bartlett J.M., Adie L., Watters A.D., Going J.J., Grigor K.M. Chromosomal aberrations in

transitional cell carcinoma that are predictive of disease outcome are independent of polyploidy.

// BJU Int. - 1999. - V.84, N.7. - P.775-779

14. Santos L., Pereira S., Leite R.P., Souto M., Amaro T., Criado B. Chromosome instability and

progression in urothelial cell carcinoma of the bladder.// B. Acta Oncol. - 2003. - V.42, N.2. -

P.169-173.

15. Cairns P., Shaw M.E., Knowles M.A. Initiation of bladder cancer may involve deletion of a

tumour-suppressor gene on chromosome 9. // Oncogene. - 1993. - V. 8. - P.1083-1085.

16. Spruck C.H., Ohneseit P.F., Gonzalez-Zulueta M., Esrig D., Miyao N., Tsai Y.C., Lerner

S.P., Schmutte C., Yang A.S., Cote R. Two molecular pathways to transitional cell carcinoma of

the bladder. // Cancer Res. - 1994. - V.54. - P.784-788.

17. Rosin M.P., Cairns P., Epstein J.I., Schoenberg M.P., Sidransky D. Partial allelotype of

carcinoma in situ of the human bladder. // Cancer Res. - 1995. - V.55. - P.5213-5216.

18. Ruppert J.M., Tokino K., Sidransky D. Evidence for two bladder cancer suppressor loci on

human chromosome 9. // Cancer Res. - 1993. - V.53. - P.5093-5095.

19. Balazs M., Carroll P., Kerschmann R., Sauter G., Waldman F.M. Frequent homozygous

deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer

detected by fluorescence in situ hybridization. // Genes Chromosomes Cancer. - 1997. - V.19. -

P.84-89.

20. Orlow I., Lacombe L., Hannon G.J., Serrano M., Pellicer I., Dalbagni G., Reuter V.E., Zhang

Z.F., Beach D., Cordon-Cardo C. Deletion of the p16 and p15 genes in human bladder tumors. //

J Natl Cancer Inst. - 1995. - V.87. - P.1524-1529.

21. Richter J., Jiang F., Gorog J.P., Sartorius G., Egenter C., Gasser T.C., Moch H., Mihatsch

M.J., Sauter G. Marked genetic differences between stage pTa and stage pT1 papillary bladder

cancer detected by comparative genomic hybridization. // Cancer Res - 1997. - V.57. - P.2860-

2864.

22. Sasaki K., Hamano K., Kinjo M., Hara S. Intratumoral heterogeneity in DNA ploidy of

bladder carcinomas. // Oncology. - 1992. - V.49. - P.219-222.

23. Shackney S.E., Berg G., Simon S.R., Cohen J., Amina S., Pommersheim W., Yakulis R.,

Wang S., Uhl M., Smith C.A. Origins and clinical implications of aneuploidy in early bladder

cancer. // Cytometry - 1995. - V.22. - P.307-316.

24. Billerey C., Lamy B., Bittard H., Rozan S., Carbillet J.P. Flow cytometry versus urinary

cytology in the diagnosis and follow-up of bladder tumors: critical review of a 5-year experience.

// World J Urol. - 1993. - V. 11. - P.156-160.

25. Zhao J., Richter J., Wagner U., Roth B., Schraml P., Zellweger T., Ackerman D., Schmid U.,

Moch H., Mihatsch M.J., Gasser T.C., Sauter G. Chromosomal imbalances in noninvasive

papillary bladder neoplasms (pTa). // Cancer Res. - 1999. - V.59. - P.4658-4661.

26. Zhang F.F., Arber D.A., Wilson T.G., Kawachi M.H., Slovak M.L. Toward the validation of

aneusomy detection by hybridizatio in situ hybridization in bladder cancer: comparative anlalysis

with cytology, cytogenetics, and clinical features predicts recurrence and defines clinical testing

limitations. // Clin Cancer Res - 1997. - V.3. - P.2317-2328.

27. Wheeless L.L., Reeder J.E., Han R., O?Connell M.J., Frank I.N., Cockett A.T., Hopman A.H.

Bladder irrigation specimens assayed by fluorescence in situ hybridization to interphase nuclei. //

Cytometry. - 1994. - V.17. - P.319-326.

28. Ramaekers F.C., Hopman A.H. Detection of genetic aberrations in bladder cancer using in

situ hybridization. // Ann NY Acad Sci - 1993. - V.677. - P.199-213.

29. Meloni A.M., Peier A.M., Haddad F.S., Powell I.J., Block A.W., Huben R.P., Todd I., Potter

W., Sandberg A.A. A new approach in the diagnosis and follow-up of bladder cancer. FISH

analysis of urine, bladder washings, and tumors. // Cancer. Genet. Cytogenet. - 1993. - V.71. -

P.105-118.

30. Pycha A., Mian C., Haitel A., Hofbauer J., Wiener H., Marberger M. Fluorescence in situ

hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder

cancer. // J Urol. - 1997. - V.157. - P.2116-2119.

31. Cajulis R.S., Haines G.K., Frias-Hidvegi D., McVary K. Interphase cytogenetics as an

adjunct in the cytodiagnosis of urinary bladder carcinoma: a comparative study of cytology, flow

cytometry and interphase cytogenetics in bladder washes. // Anal. Quant. Cytol. Histol. - 1994. -

V.16. - P.1-10.

32. Cajulis R.S., Haines G.K., Frias-Hidvegi D., McVary K., Bacus J.W. Cytology, flow

cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in

the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. // Diag.

Cytopathol. - 1995. - V.13. - P.214-223

33. Sokolova I.A., Halling K.C., Jenkins R.B., Burkhardt H.M., Meyer R.G., Seelig S.A., King

W. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the

detection of urothelial carcinoma in urine. // J. Mol. Diagn. - 2000. - V.2, N.3. - P.116-123.

34. Cianciulli A.M., Bovani R., Leonardo F., Antenucci A., Gandolfo G.M., Giannarelli D.,

Leonardo C., Iori F., Laurenti C. Interphase cytogenetics of bladder cancer progression:

relationship between aneusomy, DNA ploidy pattern, histopathology, and clinical outcome. // Int

J Clin. Lab. Res. - 2000. - V.30, N.1. - P.5-11.

35. Halling K.C., King W., Sokolova I.A. et al. A comparison of cytology and fluorescence in

situ hybridization for the detection of bladder cancer. // J. Urol. - 2000. - V.164. - P.1768-1775.

36. Halling K.C., King W., Sokolova I.A., Karnes R.J., Meyer R.G., Powell E.L., Sebo T.J.,

Cheville J.C., Clayton A.C., Krajnik K.L., Ebert T.A., Nelson R.E., Burkhardt H.M.,Ramakumar S., Stewart C.S., Pankratz V.S., Lieber M.M., Blute M.L., Zincke H., Seelig S.A.,

Jenkins R.B., O?Kane D.J. A comparison of BTA stat, hemoglobin dipstick, telomerase and

Vysis UroVysion assays for the detection of urothelial carcinoma in urine. // J Urol. - 2002. - V.

167, N.5. - P.2001-2006.

37. Sarosdy M.F., Schellhammer P., Bokinsky G., Kahn P., Chao R., Yore L., Zadra J., Burzon

D., Osher G., Bridge J.A., Anderson S., Johansson S.L., Lieber M., Soloway M., Flom K.

Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of

bladder cancer. // J Urol. - 2002. - V. 168, N.5. - P.1950-1954.

38. Quek M.L., Sanderson K., Daneshmand S., Stein J.P. New molecular markers for bladder

cancer detection. // Curr. Opin. Urol. - 2004. - V. 14, N.5. - P.259-264.

39. Mezzelani A., Dagrada G., Alasio L., Sozzi G., Pilotti S. Detection of bladder cancer by

multitarget multicolour FISH: comparative analysis on archival cytology and paraffin-embedded

tissue. // Cytopathology. - 2002. - V.13, N.5. - P.317-325.

40. Mian C., Lodde M., Comploj E., Negri G., Egarter-Vigl E., Lusuardi L., Palermo S.,

Marberger M., Pycha A. Liquid-based cytology as a tool for the performance of uCyt+ and

Urovysion Multicolour-FISH in the detection of urothelial carcinoma. // Cytopathology - 2003. -

V.14, N.6. - P.338-342.

41. Droller M.J. Bladder cancer: state-of-the art care. // CA Cancer J. Clin. - 1998. - V.48, N.5. -

P.269-284.

42. Laudadio J., Keane T.E., Reeves H.M., Savage S.J., Hoda R.S., Lage J.M., Wolff D.J.

Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for

clinical practice. // BJU Int. - 2005. - V.96, N.9. - P.1280-1285.

43. Daniely M., Rona R., Kaplan T., Olsfanger S., Elboim L., Zilberstien Y., Friberger A.,

Kidron D., Kaplan E., Lew S., Leibovitch I. Combined analysis of morphology and fluorescence

in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine

samples. // Urology. - 2005. - V.66, N.6. - P.1354-1359.

44. Lubbe L., Nowack R., May M., Ullmann K., Gunia S., Kaufmann O., Hakenberg O., Muche

J., Hoschke B. FISH-a new noninvasive method for the diagnosis of urinary bladder carcinomas.

// Clin. Lab. - 2004. - V.50, N.7-8. - P.395-402.

45. Halling K.C. Vysis UroVysion for the detection of urothelial carcinoma. // Expert Rev Mol

Diagn. - 2003. - V.3, N.4. - P.507-519.

46. Pycha A., Lodde M., Comploj E., Negri G., Egarter-Vigl E., Vittadello F., Lusuardi L.,

Palermo S., Mian C. Intermediate-risk urothelial carcinoma: an unresolved problem? // Urology.

- 2004. - V.63, N.3. - P.472-475.

WWW.MEDLINE.RU ТОМ 8, ОНКОЛОГИЯ, МАЙ 2007

Дата поступления: 11.04.2007.

47. Kruger S., Mess F., Bohle A., Feller A.C. Numerical aberrations of chromosome 17 and the

9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell

carcinoma of the urinary bladder. // Int J Oncol. - 2003. - V.23, N.1. - P.41-48.

48. Bollmann M., Heller H., Bankfalvi A., Griefingholt H., Bollmann R. Quantitative molecular

urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients

with superficial bladder cancer? // BJU Int. - 2005. - V.95, N.9. - P.1219-1225.

49. Mian C, Lodde M, Comploj E, Lusuardi L, Palermo S, Mian M, Maier K, Pycha A.

Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder

cancer. // J Clin Pathol. - 2006 - V.59 - P. 984-987.

50. Veeramachaneni R., Nordberg M.L., Shi R., Herrera G.A., Turbat-Herrera E.A. Evaluation

of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing

urothelial carcinoma. // Diagn. Cytopathol. - 2003. - V.28, N.6. - P.301-307.

51. Skacel M., Fahmy M., Brainard J.A., Pettay J.D., Biscotti C.V., Liou L.S., Procop G.W.,

Jones J.S., Ulchaker J., Zippe C.D., Tubbs R.R. Multitarget fluorescence in situ hybridization

assay detects transitional cell carcinoma in the majority of patients with bladder cancer and

atypical or negative urine cytology. // J Urol. - 2003. - V.169, N.6. - P.2101-2105.

52. Varella-Garcia M., Akduman B., Sunpaweravong P., Di Maria M.V., Crawford E.D. The

UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence

of bladder cancer. // Urol Oncol. - 2004. - V.22, N.1. - P.16-19.